Raymond James Financial Inc. Increases Stake in Smith & Nephew SNATS, Inc. $SNN

Raymond James Financial Inc. raised its position in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 27.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 259,429 shares of the medical equipment provider's stock after purchasing an additional 56,342 shares during the quarter. Raymond James Financial Inc. owned 0.06% of Smith & Nephew SNATS worth $7,360,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of SNN. J. Goldman & Co LP purchased a new position in shares of Smith & Nephew SNATS during the fourth quarter worth approximately $47,700,000. Northern Trust Corp boosted its stake in Smith & Nephew SNATS by 169.9% in the fourth quarter. Northern Trust Corp now owns 508,392 shares of the medical equipment provider's stock valued at $12,496,000 after acquiring an additional 320,054 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Smith & Nephew SNATS in the fourth quarter valued at approximately $6,132,000. D. E. Shaw & Co. Inc. lifted its stake in shares of Smith & Nephew SNATS by 340.6% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 166,587 shares of the medical equipment provider's stock worth $4,095,000 after buying an additional 128,780 shares during the period. Finally, Tocqueville Asset Management L.P. lifted its stake in shares of Smith & Nephew SNATS by 91.6% during the first quarter. Tocqueville Asset Management L.P. now owns 251,563 shares of the medical equipment provider's stock worth $7,137,000 after buying an additional 120,291 shares during the period. 25.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Canaccord Genuity Group lifted their price objective on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a "hold" rating in a research note on Monday, August 18th. Wall Street Zen raised shares of Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 30th. Six analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $36.00.

Smith & Nephew SNATS Trading Up 1.2%

Shares of Smith & Nephew SNATS stock traded up $0.45 on Friday, reaching $38.09. The company had a trading volume of 1,215,377 shares, compared to its average volume of 583,681. The firm's 50 day moving average price is $33.57 and its two-hundred day moving average price is $30.10. The firm has a market cap of $16.68 billion, a PE ratio of 17.63, a PEG ratio of 1.05 and a beta of 0.70. Smith & Nephew SNATS, Inc. has a 52-week low of $23.69 and a 52-week high of $38.41. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00.

Smith & Nephew SNATS Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 3rd will be paid a $0.285 dividend. This represents a dividend yield of 210.0%. The ex-dividend date of this dividend is Friday, October 3rd. Smith & Nephew SNATS's payout ratio is 41.20%.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.